Progression and Relapse of Pediatric Soft Tissue Sarcoma:
Individualized Approach of Treatment – Experience from a Major Pediatric
Cancer Center in Europe
Conclusion In addition to well characterized clinical factors such as
local or systemic relapse, the Oberlin score could be helpful in counselling
patients and their families for choosing the best strategy of care. [...] Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart,
GermanyArticle in Thieme eJournals: Table of contents | Abstract | Full text (Source: Klinische Padiatrie)
Source: Klinische Padiatrie - July 11, 2023 Category: Pediatrics Authors: Barnbrock, Anke Elisabeth Luckowitsch, Marie Schmidt, Stanislaw Buus-Gehrig, Constanze Koscher, Leila Becker, Martina Vokuhl, Christian Klingebiel, Thomas Lehrnbecher, Thomas Bochennek, Konrad Tags: Original Article Source Type: research
Molecules, Vol. 28, Pages 5292: Garcinol and Anacardic Acid, Natural Inhibitors of Histone Acetyltransferases, Inhibit Rhabdomyosarcoma Growth and Proliferation
In this study, the impact of the natural histone acetyltransferase inhibitors (HATi)—garcinol (GAR) and anacardic acid (AA)—on the biology of RMS cells was evaluated through a series of in vitro tests measuring proliferation, viability, clonogenicity, cell cycle and apoptosis. Moreover, using oligonucleotide microarrays and real-time PCR, we identified several genes whose expression changed after GAR and AA treatment. The examined HATi significantly reduce the invasive phenotype of RMS cells by inhibiting the growth rate, viability and clonogenic abilities. What is more, these substances cause c...
Source: Molecules - July 8, 2023 Category: Chemistry Authors: Patrycja Tomasiak Joanna Janisiak Dorota Rogi ńska Magdalena Peru żyńska Bogus ław Machaliński Maciej Tarnowski Tags: Article Source Type: research
Cancers, Vol. 15, Pages 3532: Cell-Free DNA Extracted from CSF for the Molecular Diagnosis of Pediatric Embryonal Brain Tumors
Conclusion: CSF cfDNA sequencing yielded informative results in 60% (15/25) of all cases, with informative results in 83% (15/18) of all cases analyzed by WES. These results pave the way for the implementation of these novel approaches for molecular diagnosis and minimal residual disease monitoring. (Source: Cancers)
Source: Cancers - July 7, 2023 Category: Cancer & Oncology Authors: Mathieu Chicard Yasmine Iddir Julien Masliah Planchon Val érie Combaret Val éry Attignon Alexandra Saint-Charles Didier Frappaz C écile Faure-Conter K évin Beccaria Pascale Varlet Birgit Geoerger Sylvain Baulande Gaelle Pierron Yassine Bouchoucha Fran Tags: Article Source Type: research
Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
CONCLUSIONS: The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every two weeks was safe and tolerable. This combination had a disease control rate of 22% at five months.PMID:37398992 | DOI:10.1158/1078-0432.CCR-23-0709 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - July 3, 2023 Category: Cancer & Oncology Authors: Srivandana Akshintala R Taylor Sundby Donna Bernstein John W Glod Rosandra N Kaplan Marielle E Yohe Andrea M Gross Joanne Derdak Haiyan Lei Alexander Pan Eva Dombi Isabel Palacio-Yance Kailey R Herrera Markku M Miettinen Helen X Chen Seth M Steinberg Lee Source Type: research
Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
CONCLUSIONS: The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every two weeks was safe and tolerable. This combination had a disease control rate of 22% at five months.PMID:37398992 | DOI:10.1158/1078-0432.CCR-23-0709 (Source: Cancer Control)
Source: Cancer Control - July 3, 2023 Category: Cancer & Oncology Authors: Srivandana Akshintala R Taylor Sundby Donna Bernstein John W Glod Rosandra N Kaplan Marielle E Yohe Andrea M Gross Joanne Derdak Haiyan Lei Alexander Pan Eva Dombi Isabel Palacio-Yance Kailey R Herrera Markku M Miettinen Helen X Chen Seth M Steinberg Lee Source Type: research
Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
CONCLUSIONS: The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every two weeks was safe and tolerable. This combination had a disease control rate of 22% at five months.PMID:37398992 | DOI:10.1158/1078-0432.CCR-23-0709 (Source: Cell Research)
Source: Cell Research - July 3, 2023 Category: Cytology Authors: Srivandana Akshintala R Taylor Sundby Donna Bernstein John W Glod Rosandra N Kaplan Marielle E Yohe Andrea M Gross Joanne Derdak Haiyan Lei Alexander Pan Eva Dombi Isabel Palacio-Yance Kailey R Herrera Markku M Miettinen Helen X Chen Seth M Steinberg Lee Source Type: research
Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
CONCLUSIONS: The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every two weeks was safe and tolerable. This combination had a disease control rate of 22% at five months.PMID:37398992 | DOI:10.1158/1078-0432.CCR-23-0709 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - July 3, 2023 Category: Cancer & Oncology Authors: Srivandana Akshintala R Taylor Sundby Donna Bernstein John W Glod Rosandra N Kaplan Marielle E Yohe Andrea M Gross Joanne Derdak Haiyan Lei Alexander Pan Eva Dombi Isabel Palacio-Yance Kailey R Herrera Markku M Miettinen Helen X Chen Seth M Steinberg Lee Source Type: research
Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
CONCLUSIONS: The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every two weeks was safe and tolerable. This combination had a disease control rate of 22% at five months.PMID:37398992 | DOI:10.1158/1078-0432.CCR-23-0709 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - July 3, 2023 Category: Cancer & Oncology Authors: Srivandana Akshintala R Taylor Sundby Donna Bernstein John W Glod Rosandra N Kaplan Marielle E Yohe Andrea M Gross Joanne Derdak Haiyan Lei Alexander Pan Eva Dombi Isabel Palacio-Yance Kailey R Herrera Markku M Miettinen Helen X Chen Seth M Steinberg Lee Source Type: research
The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors
Curr Oncol. 2023 May 25;30(6):5279-5298. doi: 10.3390/curroncol30060401.ABSTRACTEstablishing novel therapies for rare central nervous system (CNS) tumors is arduous due to challenges in conducting clinical trials in rare tumors. Immunotherapy treatment has been a rapidly developing field and has demonstrated improvements in outcomes for multiple types of solid malignancies. In rare CNS tumors, the role of immunotherapy is being explored. In this article, we review the preclinical and clinical data of various immunotherapy modalities in select rare CNS tumors, including atypical meningioma, aggressive pituitary adenoma, pit...
Source: Current Oncology - June 27, 2023 Category: Cancer & Oncology Authors: Andrew Rodriguez Carlos Kamiya-Matsuoka Nazanin K Majd Source Type: research
The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors
Curr Oncol. 2023 May 25;30(6):5279-5298. doi: 10.3390/curroncol30060401.ABSTRACTEstablishing novel therapies for rare central nervous system (CNS) tumors is arduous due to challenges in conducting clinical trials in rare tumors. Immunotherapy treatment has been a rapidly developing field and has demonstrated improvements in outcomes for multiple types of solid malignancies. In rare CNS tumors, the role of immunotherapy is being explored. In this article, we review the preclinical and clinical data of various immunotherapy modalities in select rare CNS tumors, including atypical meningioma, aggressive pituitary adenoma, pit...
Source: Current Oncology - June 27, 2023 Category: Cancer & Oncology Authors: Andrew Rodriguez Carlos Kamiya-Matsuoka Nazanin K Majd Source Type: research
